Measurement of Circulating Cell-Free DNA Levels by a Simple Fluorescent Test in Patients With Breast Cancer
Measurement of Circulating Cell-Free DNA Levels by a Simple Fluorescent Test in Patients With Breast Cancer
复制标题
DOI：
10.1309/ajcpi5yhg0ogfahm
复制
发表时间：
2015-01-01
影响因子：
3.5
通讯作者：
Douvdevani, Amos
中科院分区：
文献类型：
--
作者：
Agassi, Ravit;Czeiger, David;Douvdevani, Amos
目的：为了评估循环无细胞DNA（CFD）测量的一个简单的荧光检测作为生物标志物的乳腺cancer.Methods：我们招募了38例乳腺癌患者手术前，2例非癌性乳腺病变，9例患者手术后，16名健康参与者，29名对照组女性入院急诊室，并释放没有住院治疗。CFD水平通过直接荧光测定法测量。术前癌症患者的CFD水平升高（1，010 +/- 642 ng/mL），高于健康对照组的测量值（395 +/- 248 ng/mL，P < .001），非癌性乳腺病变组（386 +/- 40 ng/mL），非住院对照组（492 +/- 193 ng/mL，P <0.001），术后癌症组（398 +/- 162 ng/mL，P <0.01）。术前与健康患者组的受试者工作特征曲线下面积为0.83。CFD水平与肿瘤大小（P = 0.03，rho = 0.36）、淋巴结受累（P = 0.0003，rho = 0.56）和TNM分期（P = 0.0002，rho = 0.56）相关。所有患者腋窝淋巴结受累的CFD值大于600 ng/mL.Conclusions：CFD测量使用一个简单的荧光分析显示出良好的相关性，以阶段和增强敏感性，局部晚期疾病。需要进行一项大型前瞻性研究，以评估在乳腺X线摄影前纳入该方法作为决定性标志物是否有利。
Objectives: To evaluate circulating cell-free DNA (CFD) measured by a simple fluorescent assay as a biomarker of breast cancer.Methods: We enrolled 38 patients with breast cancer before surgery, two patients with noncancerous breast lesions, nine patients after surgery, 16 healthy participants, and 29 control women admitted to the hospital emergency ward and released without hospitalization. CFD levels were measured by a direct fluorescence assay.Results: Presurgery patients with cancer had elevated CFD levels (1,010 +/- 642 ng/mL), which were higher than those measured in the healthy control group (395 +/- 248 ng/mL, P < .001), the noncancer breast lesion group (386 +/- 40 ng/mL), the nonhospitalized control group (492 +/- 193 ng/mL, P < .001), and the postsurgery cancer group (398 +/- 162 ng/mL, P < .01). The area under the receiver operating characteristic curve of the presurgery vs healthy patient group was 0.83. CFD levels correlated with tumor size (P = .03, rho = 0.36), nodal involvement (P = .0003, rho = 0.56), and TNM stage (P = .0002, rho = 0.56). All patients with axillary node involvement had a CFD value greater than 600 ng/mL.Conclusions: CFD measured using a simple fluorometric assay has shown good correlation to stage and enhanced sensitivity to locally advanced disease. A large prospective study is warranted to evaluate if inclusion of this method as a decisive marker before mammography is advantageous.